Nissha Co.ltd. · TSE:7915
Nissha Co.ltd — Investor Presentation (June 2025)
28 slides from Nissha Co.ltd's investor presentation, Jun 24, 2025
Slide 1: Medical Market Strategy Update
Medical Market Strategy Update Medical Devices CDMO OTC Pharmaceuticals CDMO June 24, 2025 For institutional investors and analysts
Slide 2: Today's Agenda
Today's Agenda ⚫Medical Market Strategy Update ⚫Growth Strategy of Medical Devices CDMO ⚫Growth Strategy of OTC Pharmaceutical CDMO ©2025 Nissha Group 2
Slide 3: Medical Market Strategy Update
Medical Market Strategy Update Junya Suzuki Chairman of the Board and Group CEO Nissha Co., Ltd. ©2025 Nissha Group
Slide 4: Achieving stable growth in the three priority markets of Non-IT Devices
Achieving stable growth in the three priority markets of Non-IT Devices IT Devices Market Non-IT Devices Market (Smartphones and tablets) (Medical, Mobility, Sustainable Materials) Abundant business opportunities, Expecting stable growth but a rapidly changing environment ©2025 Nissha Group 4
Slide 5: The product portfolio in the medical market
The product portfolio in the medical market Companywide efforts to be taken to tackle the medical market (medical devices, pharmaceuticals, and healthcare products) high Star Problem Child ●Medical Devices CDMO Medical (Medical Technologies) OTC Devices Pharmaceutical CDMO CDMO Biomaterials ●OTC Pha
Slide 6: Medical Market Performance Trends
Medical Market Performance Trends ⚫2024 Results: Improved profitability in the Medical Technologies ⚫2025 Plan: Continued growth and improved profitability in Medical Technologies and Contribution from Shiga Pharmaceutical performance 30.0% ¥61.0 billion ¥57.5 billion ■Sales to the medical market 25
Slide 7: Medical Devices CDMO
Medical Devices CDMO Sam Heleba Executive Vice President, MTBU CEO, Nissha Medical Technologies ©2025 Nissha Group
Slide 8: Medical Devices CDMO: Our Roles
Medical Devices CDMO: Our Roles One-stop service provider from design to manufacturing Medical Devices OEM（Global Top） Distribution Marketing Design Development Verification Manufacturing Sales Product concepts Outsource Products Design Development Verification Manufacturing Medical Devices CDMO ©20
Slide 9: Medical Devices CDMO: Our Specialization (Single-use)
Medical Devices CDMO: Our Specialization (Single-use) Surgical Devices Clinical Products Medical Wearable Sensors 60% Grounding Pads Defibrillator Electrodes Minimally Invasive Surgical Devices Endoscopes, Laparoscopes, Biopsy Devices, Ablation Catheters, Surgical Robots, and Surgical Navigation Sys
Slide 10: Converging Technology is Driving Innovation
Converging Technology is Driving Innovation Healthcare Pathway Long Term Focus ⚫ Diagnosis Digital Surgery/Smart Device Medical Industry ⚫ Treatment ⚫ Robotic platforms ⚫ Post procedure ⚫ Navigation ⚫ Chronic care ⚫ Visualization ⚫ Data collection Targeted Healthcare Benefits ⚫ Connectivity Digital
Slide 11: Securing Our Growth (Programs in Pipeline)
Securing Our Growth (Programs in Pipeline) ⚫ Increasing opportunities in accordance with our enhanced CDMO capabilities and the market trend ⚫ Numerous programs in our pipeline is enabling growth for the medium term Programs in Pipeline Sales Contribution by Programs in Pipeline ■ Expected contribut
Slide 12: Pipeline Program 1
Pipeline Program 1 ⚫ Customer: Top 5 OEM ⚫ Product: Tracker for Orthopedic Surgical Robotic Platform ⚫ Category: Robotics, Visualization ⚫ Schedule ⚫ Pilot Run: 2024Q4~ ⚫ Full Volume Production Expected: 2027 ⚫ Why we have been chosen ⚫ Integrated Capabilities: Full CDMO value proposition with Devel
Slide 13: Pipeline Program 2
Pipeline Program 2 ⚫ Customer: Top 5 OEM ⚫ Product: Endoscope sheath for ENT surgery ⚫ Category: Visualization ⚫ Schedule ⚫ Pilot Run: 2025Q3~ ⚫ Full Volume Production Expected: 2028 ⚫ Why we have been chosen ⚫ Integrated Capabilities: full CDMO value proposition with Development and Manufacturing s
Slide 14: Pipeline Program 3
Pipeline Program 3 ⚫ Customer: Top 10 OEM ⚫ Product: Kidney Stone Removal Basket ⚫ Category: Steerability ⚫ Schedule ⚫ Commercialized: 2025Q4~ ⚫ Why we have been chosen ⚫ Steering of a basket with a 0.7mm shaft which is not achievable with current steering solutions available in med device market ⚫
Slide 15: Future M&A Focus (Closing the Gap)
Future M&A Focus (Closing the Gap) ⚫ Surgical Visualization ⚫ Steerability of Endoscopic Tools Miniaturized Steering ⚫ Complex catheters and min Constructs invasive device (development & manufacturing) CMOS Advanced ⚫ Miniaturized forming Integration Electronics technologies Micro Molding/Micro Asse
Slide 16: Our Investment Focus
Our Investment Focus End Use Market High Our Investment Focus Size denotes Laparo- approx. size scopic/ Our Current Revenues General Surgery CAGR (Market) Cardio- vascular Low to Mid Teens Electro High Single Digits Physio- logy Urology Micro Low Surgical Robotics Molding Low Future Growth Impact Hi
Slide 17: OTC Drug CDMO
OTC Drug CDMO Toshiyuki Yasui Representative Director of Shigaken Pharm. Ind. Co., Ltd. ©2025 Nissha Group
Slide 18: Overview of Nissha Pharmaceuticals Business
Overview of Nissha Pharmaceuticals Business Nissha Zonnebodo Sparsha Pharma Shigaken Pharm. Nissha Zonnebodo Pharma USA Pharma Others *Equity Method affiliates 18 2025 Sales Plan Manufacture and sale of Manufacture and sale of Manufacture and sale of pharmaceuticals pharmaceuticals pharmaceuticals J
Slide 19: Overview of Shigaken Pharm.
Overview of Shigaken Pharm. Company Business Manufacturing and sales of pharmaceuticals, quasi-drugs, SHIGAKEN PHARM. IND. CO., LTD.. Name Description and health-related products 879 Takino, Koka-cho, Koka-shi, Shiga Location Prefecture - Type 2 pharmaceutical manufacturing and sales business Repres
Slide 20: OTC Drug CDMO: Our Roles
OTC Drug CDMO: Our Roles One-Stop Service from formulation design to manufacturing OTC Drug Manufacturers Regulatory Product Formulation Distribution Development approval Manufacturing Planning design Sales application Product Concept Outsource product Regulatory Formulation Development approval Man
Slide 21: Capable of handling a wide range of products in various dosage forms
Capable of handling a wide range of products in various dosage forms ⚫Dosage Forms Tablets Granules Powders Capsules Liquids ⚫Number of Formulations Manufactured Extensive experience, primarily in cold remedies and antipyretic analgesics Current Total: 44 formulations Solid oral formulations: 32 Liq
Slide 22: OTC drugs are outpacing prescription drugs in growth
OTC drugs are outpacing prescription drugs in growth Pharmaceuticals Growth drivers Government healthcare containment policy Prescription Drugs OTC Drugs ⚫ Promotion of self-medication ⚫ Prescription required ⚫ Available at pharmacies and ⚫ Promotion of switch OTC ⚫ Domestic market size: drugstores
Slide 23: Strong growth expected in OTC drug CDMO market
Strong growth expected in OTC drug CDMO market Pharma companies increasingly outsourcing manufacturing ⚫ Focus shifting to planning and marketing CDMOs prioritize prescription drug supply ⚫ GMP violations have led to ongoing supply shortage of prescription drugs, which requires CDMOs to react urgent
Slide 24: Strengths of Shigaken Pharm.
Strengths of Shigaken Pharm. Formulation Design Track Record Capabilities ⚫ Long-standing experience as a CDMO ⚫ Advanced formulation and analysis for ⚫ Stable transactions with major diverse OTC APIs pharmaceutical manufacturers ⚫ Accumulated manufacturing expertise ⚫ Capability to support high-dif
Slide 25: Partnerships with OTC drug manufacturers and drugstores
Partnerships with OTC drug manufacturers and drugstores DAIICHI SANKYO HEALTHCARE CO., LTD. Kowa Company., Ltd. KYUSHIN PHARMACEUTICAL CO., LTD. Shiono Chemical Co., Ltd. Sato Pharmaceutical Co., Ltd. TOKIWA Pharmaceutical Co., Ltd. Zenyaku Kogyo Co., Ltd. Shiraishiyakuhin.co., Ltd. ©2025 Nissha Gro
Slide 26: Customer Feedback
Customer Feedback Quality & Technical Speed & Responsiveness Reliability Capability Fast and quick launch Quick response to Stable supply even High formulation of production transfer raw material changes, when competitors development skills from another company contributing to stable face shortages
Slide 27: Becoming the No.1 OTC drug CDMO through synergies with Nissha Group
Becoming the No.1 OTC drug CDMO through synergies with Nissha Group JPY12.0 ⚫ Lead Expansion billion 2x ⚫ Enhanced recognition and credibility through New increase integration into Nissha Group Leads ⚫ Increased inquiries driven by expectations for JPY5.0 billion Ordered production capacity expansio
Slide 28: Among the information included in this presentation and provided at investor briefings and conferences,
Among the information included in this presentation and provided at investor briefings and conferences, performance targets, plans, outlooks, strategies and other information that is not constituted of actual past facts, is information that has been judged reasonable by the managers of the Company b